Henrietta Lacks HeLa cells

Henrietta Lacks HeLa cells are, by any reasonable measure, one of the most important tools in the entire history of medicine. They helped develop the polio vaccine. They’ve been used in cancer research, in vitro fertilization, gene mapping, radiation studies, and — seventy years after they were first taken — COVID-19 vaccine development. Scientists have grown an estimated 50 million metric tons of them since 1951, distributed to laboratories in essentially every country doing biomedical research. If you’ve ever benefited from a modern vaccine, a cancer treatment, or a fertility procedure, there’s a real chance that some part of the research pipeline that made it possible ran through cells that came from one specific woman’s body.

She never knew any of this happened. She died believing doctors were treating her cancer. She had no idea a piece of her tumor had been kept, grown, multiplied, shipped around the world, and eventually sold, in various forms, by biotechnology companies that built real revenue on top of it. Her family didn’t find out for twenty years. When they did find out, it wasn’t because anyone at the hospital told them out of a sense of obligation. It was because researchers needed more samples from her children to study the cells further, and simply asked, without much explanation of why.

I’ve written a few stories on this blog now about scientific credit going to the wrong place — Rosalind Franklin, Lise Meitner, the myth-and-reality gap in Grace Hopper’s moth. Henrietta Lacks’s story is different from all of those in a specific way that I think matters. This isn’t really about credit at all. She never asked for credit, and her family, for decades, wasn’t even fighting for recognition in the way the other stories in this series involve. They were fighting for something more basic: to be told what happened, and to have some say in what continued to happen, to tissue that was still, undeniably, made of her.

Henrietta Lacks HeLa cells medical history consent

Table of Contents

A Segregated Ward and a Piece of Tissue

Henrietta Lacks was born in 1920 in Roanoke, Virginia, and grew up working tobacco fields in Clover, Virginia, before eventually moving to Baltimore County, Maryland with her husband during the wartime industrial boom of the 1940s. She married her cousin David “Day” Lacks at 14 and had five children with him.

In early 1951, at 31 years old, she noticed persistent vaginal bleeding and went to Johns Hopkins Hospital — one of the only major hospitals in the region that would treat Black patients at all, at a time when Baltimore’s medical system, like most of the American South, operated under formal racial segregation. She was diagnosed with an aggressive form of cervical cancer and admitted to what the hospital’s own records referred to plainly as “the ward for colored women.”

During a treatment procedure, while she was under anesthesia, a surgeon shaved a small sample of tissue from her tumor, along with a sample of healthy cervical tissue nearby, without informing her and without asking her permission. That tissue was sent to Dr. George Gey, a researcher at Johns Hopkins who had spent years trying, mostly unsuccessfully, to keep human cells alive and dividing outside the human body — a goal that had eluded virtually every researcher who’d attempted it, since most human cell cultures simply died after a limited number of divisions.

Henrietta’s cells didn’t die. They kept dividing, roughly every 24 hours, indefinitely. Gey’s assistant, Mary Kubicek, was the one who actually cultured them, using a mixture that included chicken plasma, in the small lab where this kind of quiet, unglamorous work happened. Nobody in that lab, as far as the historical record shows, fully understood in that moment what they’d actually created. They understood it was unusual. They didn’t yet understand it was going to become one of the most consequential biological materials of the century.

I find something specifically unsettling about the ordinariness of that moment — a routine biopsy, extra tissue that would normally have just been discarded, handed instead to a researcher because it happened to be there and he happened to be trying something new. Nobody set out to build a foundational tool for medical research using a woman’s body without her knowledge. It just quietly happened that way, inside a system where a Black woman’s tissue, taken during treatment in a segregated ward, wasn’t considered something requiring her permission to keep.

What Made Her Cells Different

Understanding why Henrietta’s cells mattered requires understanding what almost every human cell sample does when researchers try to keep it alive in a lab.

Normal human cells divide a limited number of times — typically somewhere between 40 and 60 divisions — before they stop, a biological limit that had made it essentially impossible, before 1951, to run a long-term experiment using consistent, identical human cells across multiple labs over multiple years. Every study had to work around cells that would eventually senesce and die, introducing variability that made certain kinds of research genuinely difficult to do reliably.

Henrietta’s cells didn’t stop. Researchers later discovered why: her tumor had been infected with a strain of human papillomavirus that had disrupted the genes responsible for normal, limited cell division, effectively removing the biological brakes that stop ordinary cells from dividing forever. The result was what’s now called an “immortalized” cell line — cells that could, in principle, keep dividing without end, genetically consistent, endlessly reproducible, available in essentially unlimited quantity to any lab that wanted them.

For researchers, this was close to a miracle. For the first time, scientists anywhere in the world could run experiments on identical human cells, compare results across labs and across decades, and build cumulative knowledge on a shared, stable biological foundation rather than starting over with fresh, inconsistent samples every time. Named “HeLa,” using the first two letters of Henrietta’s first and last names — ostensibly to protect her anonymity, though her actual identity would eventually become widely known anyway — the cell line was distributed to labs around the world within just a few years, and it never stopped being useful.

As someone who thinks a fair amount about infrastructure — the unglamorous, foundational layers that everything else gets built on top of — I find the HeLa story genuinely striking in this specific sense. It wasn’t a single discovery. It was closer to building a piece of shared infrastructure that thousands of subsequent discoveries would depend on, quietly, for decades, the way modern software depends on protocols nobody thinks about until they fail. Except this particular piece of infrastructure was a living, dividing part of an actual person, and that person never knew her body had become the foundation other people’s careers, and other companies’ profits, would eventually be built on.

Twenty Years of Not Knowing

Henrietta Lacks died on October 4, 1951, less than a year after her diagnosis, at 31 years old. She was buried in an unmarked grave in a family cemetery in Virginia. Her cells, meanwhile, were already being cultured, distributed, and used in research around the world — a genuinely strange asymmetry, a piece of her body actively thriving and multiplying in laboratories globally while the rest of her had already been laid to rest.

Her family had no idea any of this was happening. Not months later. Not years later. For roughly two decades, David Lacks and his children lived their lives — struggling financially, largely without reliable health insurance, several of them in and out of difficult circumstances — with absolutely no knowledge that Henrietta’s cells were, at that exact moment, one of the most widely used research tools in the world, generating scientific breakthroughs and, eventually, real commercial revenue for the companies that grew and sold them.

The family finally learned what had happened in the mid-1970s, and even then, not through any deliberate act of disclosure. Researchers studying HeLa cells needed blood samples from Henrietta’s biological children to help address a genuinely embarrassing scientific problem — HeLa cells had turned out to be so robust and fast-growing that they’d contaminated numerous other cell lines in labs around the world, and researchers needed genetic markers from the family to help sort out which samples were actually HeLa and which had been silently overtaken by it. The Lacks family learned, essentially as a side effect of a lab logistics problem, that their mother’s cells had been alive and multiplying in labs across the planet for more than twenty years.

I try to imagine receiving that phone call, and I find I genuinely can’t get all the way there. Not “your mother’s legacy lives on” in some comforting, abstract sense. A literal, physical piece of her — dividing, being bought and sold, sitting in refrigerators in laboratories on multiple continents — and nobody had thought to mention it. For two decades. The family’s first real information about what had happened came wrapped inside someone else’s inconvenience, not as an act of respect toward them or toward her.

What Nobody Compensated Them For

The ethical dimensions of this story extend well beyond the original lack of consent, because the way HeLa cells were subsequently commercialized raises a genuinely separate set of questions.

Johns Hopkins itself has stated it never directly profited from distributing HeLa cells, and freely provided the original line to researchers who requested it. But a substantial biotechnology industry grew up around the cells over the following decades — companies culturing, packaging, and selling HeLa-derived products, research kits, and services, generating what has been described in litigation as billions of dollars in cumulative revenue across the industry, built on a cell line whose origin traces to tissue taken without permission from a woman whose own family, for most of that time, couldn’t reliably afford health insurance.

In October 2021, Henrietta’s estate filed suit against Thermo Fisher Scientific, a biotechnology company with more than $40 billion in annual revenue, arguing that the company had continued knowingly commercializing products derived from HeLa cells long after the circumstances of their origin had become widely known and publicly documented — including, notably, on the company’s own website. Thermo Fisher initially sought to have the case dismissed on statute-of-limitations grounds. On August 1, 2023 — what would have been Henrietta’s 103rd birthday — the two parties reached a confidential settlement.

Family attorney Ben Crump described the moment plainly: “There couldn’t have been a more fitting day for her to have justice, for her family to have relief. It was a long fight — over 70 years — and Henrietta Lacks gets her day.” Additional lawsuits against other companies that have commercialized HeLa-derived products have followed.

I keep sitting with that specific number: seventy years. From an unconsented biopsy in a segregated hospital ward in 1951 to a confidential legal settlement in 2023 — an entire human lifetime, longer than Henrietta herself got to live, elapsed between the original act and any form of acknowledgment that reached the people who’d actually been harmed by it. I don’t know what to do with a gap that wide except note it plainly, the way you note any fact too large to compress into something more comfortable.

What HeLa Actually Built

It’s worth being concrete about the scale of what came out of this, because the scientific impact genuinely is difficult to overstate.

HeLa cells were used to test and help develop the polio vaccine in the early 1950s, at a moment when polio was one of the most feared diseases in America, paralyzing and killing thousands of children every year. They’ve been central to cancer research, to studies of radiation and toxin exposure, to gene mapping efforts that eventually contributed to the Human Genome Project, to the development of in vitro fertilization techniques, and, decades later, to research supporting COVID-19 vaccine development. They were even sent into orbit, used in some of the earliest research into how human cells behave in zero gravity.

Rebecca Skloot’s 2010 book, The Immortal Life of Henrietta Lacks, is largely responsible for finally bringing this full story to a wide public audience, treating Henrietta as an actual person rather than simply the biological source material behind a famous cell line — her own hopes, her children, the specific texture of her actual life, alongside the scientific legacy that had, for so long, existed almost entirely separate from any memory of who she’d been. The book became a bestseller and was later adapted into a film. In 2013, following renewed public attention, the National Institutes of Health formally agreed to give the Lacks family a say in how Henrietta’s genetic data would be accessed by researchers going forward — a genuinely meaningful, if very overdue, acknowledgment that the family had standing in decisions about tissue that was, undeniably, still made of their mother and grandmother.

A Thought to Leave You With

What stays with me most about this story isn’t really the science, remarkable as it genuinely is. It’s the specific, quiet cruelty of the twenty-year gap — not being lied to, exactly, but simply never being told, existing entirely outside a conversation that was, by any reasonable standard, about them.

I think about consent differently after sitting with this story for a while. It’s tempting to treat consent as a formality — a box checked, a form signed, a procedural step that either happened or didn’t. But what actually seems to have been missing here wasn’t just a signature. It was any sense that Henrietta Lacks, and later her family, were people whose knowledge of what was happening to her body actually mattered, independent of whatever scientific value that body’s tissue turned out to have. The cells were treated as valuable immediately. The person they came from, and the people who loved her, were treated as an afterthought for two full decades.

Modern research ethics — informed consent requirements, institutional review boards, the entire regulatory apparatus that now governs how human tissue can be used in research — exists substantially because of what happened to Henrietta Lacks and cases like hers. That’s a real, meaningful legacy, and it’s one that has genuinely protected people in the decades since. But I don’t think that legacy should be allowed to smooth over the specific, uncomfortable fact underneath it: the protections exist now because someone wasn’t protected first, and the correction, however real, arrived generations after the person who most needed it had already been buried in an unmarked grave in Virginia.

Fifty million metric tons of cells, grown from one woman’s tumor, are sitting in laboratories on every inhabited continent right now, still dividing, still being used to save other people’s lives. She’s still there, in a sense no other person in this series quite matches — not remembered through her ideas or her name attached to a unit of measurement, but literally, physically, continuously present in nearly every hospital and research institution in the world. It took seventy years for anyone to formally acknowledge that presence was owed something. It shouldn’t have taken that long to simply be told.

Henrietta Lacks: Her Cells Changed Medicine, and No One Asked Her